WILLIAM G WIERDA to T-Lymphocytes
This is a "connection" page, showing publications WILLIAM G WIERDA has written about T-Lymphocytes.
Connection Strength
0.686
-
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93.
Score: 0.106
-
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 01; 96(9):2917-24.
Score: 0.075
-
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
Score: 0.072
-
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
Score: 0.058
-
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
Score: 0.056
-
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151.
Score: 0.052
-
CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep. 2013 Mar; 8(1):60-70.
Score: 0.044
-
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.
Score: 0.044
-
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2022 07; 63(7):1566-1579.
Score: 0.021
-
T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001 Sep; 15(9):1451-7.
Score: 0.020
-
Immunogenetic therapy for B-cell malignancies. Semin Oncol. 2000 Dec; 27(6 Suppl 12):104-9.
Score: 0.019
-
Gene therapy of hematologic malignancies. Semin Oncol. 2000 Oct; 27(5):502-11.
Score: 0.019
-
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020 02; 61(2):445-449.
Score: 0.017
-
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531.
Score: 0.015
-
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
Score: 0.014
-
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22.
Score: 0.012
-
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013 Aug 01; 122(5):734-7.
Score: 0.011
-
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009 Mar 26; 113(13):3050-8.
Score: 0.008
-
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7.
Score: 0.008
-
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9.
Score: 0.008
-
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
Score: 0.007